Authors: | Partridge, A.; Zheng, Y.; Rosenberg, S.; Gelber, R.; Gelber, S.; Barry, W.; Dang, C.; Yardley, D.; Isakoff, S.; Valero, V.; Faggen, M.; Mulvey, T.; Bose, R.; Weckstein, D.; Wolff, A.; Reeder-Hayes, K.; Rugo, H.; Ramaswamy, B.; Zuckerman, D.; Hart, L.; Gadi, V.; Constantine, M.; Cheng, K.; Briccetti, F.; Schneider, B.; Garrett, M.; Marcom, P. K.; Albain, K.; Defusco, P.; Tung, N.; Ardman, B.; Nanda, R.; Jankowitz, R.; Demeo, M.; Burstein, H.; Winer, E. P.; Krop, I.; Tolaney, S. |
Abstract Title: | Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel + trastuzumab (TH) (ATEMPT) trial (TBCRC 033) |
Meeting Title: | 42nd Annual San Antonio Breast Cancer Symposium (SABCS) |
Journal Title: | Cancer Research |
Volume: | 80 |
Issue: | 4 Suppl. |
Meeting Dates: | 2019 Dec 10-14 |
Meeting Location: | San Antonio, TX |
ISSN: | 0008-5472 |
Publisher: | American Association for Cancer Research |
Date Published: | 2020-02-01 |
Language: | English |
ACCESSION: | WOS:000527012503263 |
DOI: | 10.1158/1538-7445.Sabcs19-pd10-02 |
PROVIDER: | wos |
Notes: | Meeting Abstract: PD10-02 -- Source: Wos |